Multiple sclerosis: symptomatic treatment.
Reports of new therapeutic agents designed to suppress inflammatory processes in multiple sclerosis have excited much interest but, thus far, have had little influence on symptoms, disability and handicap in patients. The clinical application of recent advances in physical, pharmacological and surgical approaches to management will, at least in the medium-term future, therefore offer significantly greater opportunities for improving the quality of life of patients with multiple sclerosis. Here, symptomatic treatment of the whole range of difficulties encountered by patients with multiple sclerosis is reviewed in the context of the multidisciplinary strategy crucial to an optimal outcome.
Thompson
A J
AJ
Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
D001831:Body Temperature; D003072:Cognition Disorders / Q000209:etiology / Q000628:therapy; D003679:Deglutition; D005121:Extremities / Q000503:physiopathology; D005221:Fatigue; D006801:Humans; D007422:Intestines / Q000503:physiopathology; D009069:Movement Disorders / Q000209:etiology / Q000628:therapy; D009103:Multiple Sclerosis / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D059408:Pain Management; D012735:Sexual Dysfunction, Physiological / Q000209:etiology / Q000628:therapy; D013060:Speech; D001743:Urinary Bladder / Q000503:physiopathology; D014786:Vision Disorders / Q000209:etiology / Q000628:therapy